Portage Biotech (NASDAQ:ATON) & Evofem Biosciences (NASDAQ:EVFM) Head-To-Head Analysis

Portage Biotech (NASDAQ:ATON) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares Portage Biotech and Evofem Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$6.77 million	($8.18)	-0.04
Evofem Biosciences	$11.39 million	0.10	$52.98 million	($0.07)	-0.12

Evofem Biosciences has higher revenue and earnings than Portage Biotech. Evofem Biosciences is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Portage Biotech and Evofem Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1	0	1	0	2.00
Evofem Biosciences	0	0	0	0	0.00

Portage Biotech currently has a consensus target price of $2.00, suggesting a potential upside of 502.41%. Given Portage Biotech’s stronger consensus rating and higher possible upside, equities analysts clearly believe Portage Biotech is more favorable than Evofem Biosciences.

Risk and Volatility

Portage Biotech has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the S&P 500.

Profitability

This table compares Portage Biotech and Evofem Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

Portage Biotech beats Evofem Biosciences on 8 of the 13 factors compared between the two stocks.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.